Literature DB >> 6337699

Tumor size and regional lymph node metastasis in colorectal cancer. A preliminary analysis from the NSABP clinical trials.

N Wolmark, I Cruz, C K Redmond, B Fisher, E R Fisher.   

Abstract

This study explores the relationships between tumor size and regional lymph node involvement in patients with Dukes' B and C colorectal cancer in the randomized prospective clinical trials of the NSABP. Six-hundred and seventy patients with colon cancer and 236 patients with carcinoma of the rectum were available for analysis. Utilizing cumulative frequency distributions of tumor diameter and tumor volume, comparisons were carried out between Dukes' B and C lesions. The results indicate that there was no correlation between the longest diameter of the primary tumor and the status of regional lymph nodes for either colon or rectal cancer. Moreover, this lack of association was evident throughout the distribution. When tumor volume was analyzed, Dukes' B tumors proved to be consistently larger than Dukes' C lesions. This inverse relationship was statistically significant for carcinoma of the rectum. These findings underscore the unique biological behavior of colorectal cancer and emphasize the function of the current generation of randomized prospective trials in providing natural history information.

Entities:  

Mesh:

Year:  1983        PMID: 6337699     DOI: 10.1002/1097-0142(19830401)51:7<1315::aid-cncr2820510723>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Local curative treatment of rectal cancer.

Authors:  U Hildebrandt
Journal:  Int J Colorectal Dis       Date:  1991-05       Impact factor: 2.571

2.  Role of Akt2 in regulation of metastasis suppressor 1 expression and colorectal cancer metastasis.

Authors:  E Agarwal; C M Robb; L M Smith; M G Brattain; J Wang; J D Black; S Chowdhury
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

3.  Morphological predictors of survival in colorectal carcinoma: univariate and multivariate analysis.

Authors:  P Schmitz-Moormann; G W Himmelmann; U Baum; M Nilles
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

4.  The prognostic value of the modifications of the Dukes' C class of colorectal cancer. An analysis of the NSABP clinical trials.

Authors:  N Wolmark; B Fisher; H S Wieand
Journal:  Ann Surg       Date:  1986-02       Impact factor: 12.969

5.  An analysis of survival and treatment failure following abdominoperineal and sphincter-saving resection in Duke's B and C rectal carcinoma. A report of the NSABP clinical trials.

Authors:  J M Henderson; M H Kutner
Journal:  Ann Surg       Date:  1987-08       Impact factor: 12.969

Review 6.  The pros and cons of fecal occult blood testing for colorectal neoplasms.

Authors:  J B Simon
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

7.  The relationship between tumour volume and the extent of spread in colorectal carcinoma.

Authors:  K W Scott; R H Grace
Journal:  Int J Colorectal Dis       Date:  1994       Impact factor: 2.571

8.  Absence of a relationship of size of primary colon carcinoma with metastasis and survival.

Authors:  W Miller; D Ota; G Giacco; V Guinee; T Irimura; G Nicolson; K Cleary
Journal:  Clin Exp Metastasis       Date:  1985 Jul-Sep       Impact factor: 5.150

9.  The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials.

Authors:  N Wolmark; B Fisher; H S Wieand; R S Henry; H Lerner; S Legault-Poisson; P J Deckers; N Dimitrov; P H Gordon; P Jochimsen
Journal:  Ann Surg       Date:  1984-04       Impact factor: 12.969

10.  An analysis of survival and treatment failure following abdominoperineal and sphincter-saving resection in Dukes' B and C rectal carcinoma. A report of the NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project.

Authors:  N Wolmark; B Fisher
Journal:  Ann Surg       Date:  1986-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.